The present invention relates to a system for producing artificial osseous tissue comprising: a client computer acquiring an image information of a subject bone tissue from an imaging unit that picks up an image of a subject bone tissue of a patient to generate a 3D image information; a server computer identifying the subject bone tissue based on the image information of the subject bone tissue received from the client computer, generating a 3D image information of at least one therapeutic bone tissue model corresponding to the subject bone tissue, and transmitting the 3D image information of the at least one therapeutic bone tissue model to the client computer; and a machining unit for fabricating an artificial bone tissue based on the 3D image information of the therapeutic bone tissue model determined from the server computer.

The present invention relates to a system for producing artificial osseous tissue comprising: a client computer acquiring an image information of a subject bone tissue from an imaging unit that picks up an image of a subject bone tissue of a patient to generate a 3D image information; a server computer identifying the subject bone tissue based on the image information of the subject bone tissue received from the client computer, generating a 3D image information of at least one therapeutic bone tissue model corresponding to the subject bone tissue, and transmitting the 3D image information of the at least one therapeutic bone tissue model to the client computer; and a machining unit for fabricating an artificial bone tissue based on the 3D image information of the therapeutic bone tissue model determined from the server computer.

A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

A scaffold comprised of a plurality of PLLA layers, which may include stem cells, for regenerating bone or tissue. The PLLA layers are separated by a plurality of hydrogel layers. The PLLA layers comprise a nanofiber mesh having a piezoelectric constant to apply an electrical charge to the bone or tissue upon application of ultrasound energy.

A scaffold comprised of a plurality of PLLA layers, which may include stem cells, for regenerating bone or tissue. The PLLA layers are separated by a plurality of hydrogel layers. The PLLA layers comprise a nanofiber mesh having a piezoelectric constant to apply an electrical charge to the bone or tissue upon application of ultrasound energy.

A bone-repair composite includes a core and a sheath. The core is a first primary unit including a combination of a first set of yarns coated with a calcium phosphate mineral layer. The first set of yarns being made from a first group of one or more polymers. The sheath is a second primary unit a combination of a second set of yarns or one or more polymer coatings. The second set of yarns being made from a second group of one or more polymers, wherein the composite is made by covering the core with the sheath, and the composite is compression molded to allow the sheath to bond to the core. The bone-repair composite has a bending modulus comparable to that of a mammalian bone, such that the ratio of the core to the sheath is provided to maximize the mechanical strength of the bone-repair composite to mimic the mammalian bone.

The present invention relates to a method of providing a graft scaffold for cartilage repair, particularly in a human patient. The method of the invention comprising the steps of providing particles and/or fibres; providing an aqueous solution of a gelling polysaccharide; providing mammalian cells; mixing said particles and/or fibres, said aqueous solution of a gelling polysaccharide and said mammalian cells to obtain a printing mix; and depositing said printing mix in a three-dimensional form. The invention further relates to graft scaffolds and grafts obtained by the method of the invention.

The present invention relates to a method of providing a graft scaffold for cartilage repair, particularly in a human patient. The method of the invention comprising the steps of providing particles and/or fibres; providing an aqueous solution of a gelling polysaccharide; providing mammalian cells; mixing said particles and/or fibres, said aqueous solution of a gelling polysaccharide and said mammalian cells to obtain a printing mix; and depositing said printing mix in a three-dimensional form. The invention further relates to graft scaffolds and grafts obtained by the method of the invention.

The present invention relates to the controllable degradation, filling-type complex bone implant of multivariant amino acid polymer-organic calcium/phosphorus salts, as well as to the preparative method thereof. The complex bone implant is consisted of multivariant amino acid polymers and medically acceptable organic calcium/phosphorus salts, while the content of organic calcium/phosphorus salts is 20-90% based on the total mass of composite material; the multivariant amino acid polymer is polymerized by ε-aminocaproic acid and at least two other amino acids, in which the molar content of ε-aminocaproic acid is at least 50% of the total molar quantity of amino acid polymers, while the amounts of other amino acids are at least 0.5% of the total molar quantity of amino acid polymers.